Benefit-Risk Assessment of Mylabris Preparations in the Treatment of Primary Hepatic Carcinoma
JIANG Hao, ZHANG Zhiqi, ZHANG Bing, ZHANG Xiaomeng, GENG Kexin
Chinese Journal of Pharmacovigilance . 2021, (6): 525 -531 .  DOI: 10.19803/j.1672-8629.2021.06.07